Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bryophyllum

Phase 3Small molecule

UUniversity of Zurich

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Menstrual PainActive, not recruiting

Menstrual PainPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q4 2028

Post-ApprovalActive, not recruiting

Menstrual Pain

NCT06908044

Clinical

Trials by Indication[1]

Overactive Bladder1 trial

Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder

Terminated·UUniversity of Zurich·Phase 2/3·NCT02129816·9 enrolled

Preterm Delivery1 trial

The Impact of Bryophyllum on Preterm Delivery

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00163579·26 enrolled

Menstrual Pain1 trial

Assessing the Therapeutic Potential of a Traditional Botanical Remedy for Menstrual Pain: Insights From a Prospective Observational Analysis

Active, not recruiting·UUniversity of Zurich·Phase 4·NCT06908044·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Bryophyllum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bryophyllum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bryophyllum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Zurich

Related News